{{Rsnum
|rsid=12963484
|Gene=FHOD3
|Chromosome=18
|position=36536338
|Orientation=plus
|GMAF=0.4646
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=FHOD3
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 29.7 | 46.8 | 23.4
| HCB | 21.3 | 47.1 | 31.6
| JPT | 17.7 | 42.5 | 39.8
| YRI | 35.9 | 45.5 | 18.6
| ASW | 35.1 | 47.4 | 17.5
| CHB | 21.3 | 47.1 | 31.6
| CHD | 21.1 | 49.5 | 29.4
| GIH | 40.6 | 53.5 | 5.9
| LWK | 28.4 | 52.3 | 19.3
| MEX | 48.3 | 46.6 | 5.2
| MKK | 34.2 | 52.3 | 13.5
| TSI | 32.4 | 52.0 | 15.7
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs12963484
|Name_s=
|Gene_s=FHOD3
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00006. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109401
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs12963484
|overall_frequency_n=64
|overall_frequency_d=128
|overall_frequency=0.5
|n_genomes=37
|n_genomes_annotated=0
|n_haplomes=55
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | Illumina Human 1M}}
{{on chip | NatGeo2}}